Conference on Antibody-Based Therapeutics for Cancer

基于抗体的癌症治疗会议

• 批准号: 6884292
• 负责人: Louis M. Weiner
• 金额: $ 0.5万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-10 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6884292
• 关键词: antitumor antibody; meeting /conference /symposium; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer therapy; phage display; travel

DESCRIPTION (provided by applicant): Monoclonal antibodies have emerged as important therapeutic vehicles for the treatment of cancer and other human diseases. Selected unconjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphomas. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new targets, including structurally defined (e.g., through proteomic or genomic screening) and functionally-defined approaches. New approaches are needed to harness the ability of antibodies to initiate and sustain innate and adaptive immune responses. For immunoconjugate strategies to consistently succeed without undue host toxicity, new strategies must be developed to dissociate the process of antibody distribution from the effects of antibody-directed tumor targeting. This meeting will address these challenges in distinct sessions devoted to antibody structure and function, immunoconjugates, antibodies as tools for target discovery, antibodies as signaling agents and immune effectors, and in a session that highlights clinical advances in the field. Leaders in each of these areas will present their work and discussion periods will be used to highlight areas felt to have particular promise. New directions for this maturing field will be emphasized in all presentations.

描述（由申请人提供）：单克隆抗体已成为用于治疗癌症和其他人类疾病的重要治疗工具。 选定的未结合的抗体可以在诸如乳腺癌和淋巴瘤等重要癌症中发挥临床意义上有意义的抗肿瘤作用。 这些令人兴奋的结果的基础机制仍有待阐明，但很可能包括诱导宿主免疫反应以及通过生长因子受体的信号传导扰动。 抗体结合物已用于提供有毒原理，例如放射性颗粒，化学疗法剂和催化毒素，并在确定的临床环境中越来越成功。 抗体工程的进步允许对靶向和功效的结构操作进行系统的评估。 具有新颖特异性的抗体可以从天真和免疫的噬菌体显示库中脱离，使其易于轻松。 在这个迅速发展的领域中的主要挑战包括开发改进的手段，用于识别新目标，包括结构定义的（例如，通过蛋白质组学或基因组筛选）和功能定义的方法。 需要采用新的方法来利用抗体启动和维持先天和适应性免疫反应的能力。 为了使免疫轭策略在没有过度宿主毒性的情况下始终如一地成功，必须制定新的策略，以将抗体分布的过程与抗体指导的肿瘤靶向的影响分离。 这次会议将在专门针对抗体结构和功能的不同会议上解决这些挑战，免疫偶联物，抗体作为目标发现的工具，抗体作为信号剂和免疫效应子，以及强调该领域临床进展的会议。 这些领域中每个领域的领导者都将展示他们的工作，讨论期将被用来突出有特殊希望的领域。 在所有演讲中将强调这个成熟领域的新方向。